Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management

References

• AlzahraniASRaefHSultanA2002Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancerJ Endocrinol Invest255263112109624
   PubMed Web of Science ®Google Scholar
• BarbaroDBoniGMeucciG2003Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablationJ Clin Endocrinol Metab884110512970272
   PubMed Web of Science ®Google Scholar
• BarbaroDBoniGMeucciG2006Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnantsNucl Med Commun276273216829763
   PubMed Web of Science ®Google Scholar
• BaudinEDo CaoCCailleuxAF2003Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patientsJ Clin Endocrinol Metab8811071112629092
   PubMed Web of Science ®Google Scholar
• BergGLindstedtGSuurkulaM2002Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormoneJ Endocrinol Invest25445211883865
   PubMed Web of Science ®Google Scholar
• BorgetICoroneCNocaudieM2007Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawalEur J Endocrinol156531817468188
   PubMed Web of Science ®Google Scholar
• BorgetIRemyHChevalierJ2008Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogenEur J Nucl Med Mol Imaging3514576318385999
   PubMed Web of Science ®Google Scholar
• Botella-CarreteroJIGalanJMCaballeroC2003Quality of life and psychometric functionality in patients with differentiated thyroid carcinomaEndocr Relat Cancer106011014713270
   PubMed Web of Science ®Google Scholar
• BragaMRingelMDCooperDS2001Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administrationJ Clin Endocrinol Metab8651485111701668
   PubMed Web of Science ®Google Scholar
• BrownAPChenJHitchcockYJ2008The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancerJ Clin Endocrinol Metab935041518029468
   PubMed Web of Science ®Google Scholar
• CailleuxAFBaudinETravagliJP2000Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?J Clin Endocrinol Metab85175810634383
   PubMed Web of Science ®Google Scholar
• CastagnaMGBrilliLPilliT2008Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levelsJ Clin Endocrinol Metab93768117971424
   PubMed Web of Science ®Google Scholar
• CooperDSDohertyGMHaugenBR2006Management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid161094216420177
   PubMed Web of Science ®Google Scholar
• CrocettiUDuranteCAttardM2008Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patientsThyroid1810495318816184
   PubMed Web of Science ®Google Scholar
• DamHQKimSMLinHC2004131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanningRadiology2325273315286323
   PubMed Web of Science ®Google Scholar
• de KeizerBBransBHoekstraA2003Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapyEur J Nucl Med Mol Imaging303677312634964
   PubMed Web of Science ®Google Scholar
• de KeizerBHoekstraAKonijnenbergMW2004Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancerJ Nucl Med4515495415347723
   PubMed Web of Science ®Google Scholar
• DumontJELamyFRogerP1992Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factorsPhysiol Rev72667971320763
   PubMed Web of Science ®Google Scholar
• EdmondsCJHayesSKermodeJC1977Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodineBr J Radiol50799807588901
   PubMed Web of Science ®Google Scholar
• EliseiRCoroneCDriedgerA2007Follow-up of differentiated thyroid (DTC) cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after recombinant human thyrotropin (rhTSH) or thyroid hormone withdrawalHorm Res6833
   Google Scholar
• GiustiMSibillaFCappiC2005A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinomaJ Endocrinol Invest2859960816218042
   PubMed Web of Science ®Google Scholar
• GoffmanTIoffeVTuttleM2003Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinomaThyroid138273014558927
   PubMed Web of Science ®Google Scholar
• GrunwaldFMenzelCFimmersR1996Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancerJ Nucl Med37196248970514
   PubMed Web of Science ®Google Scholar
• HanscheidHLassmannMLusterM2006Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalJ Nucl Med476485416595499
   PubMed Web of Science ®Google Scholar
• HaugenBRPaciniFReinersC1999A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancerJ Clin Endocrinol Metab8438778510566623
   PubMed Web of Science ®Google Scholar
• HoeFMCharronMMoshangTJr2006Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid carcinomaJ Pediatr Endocrinol Metab19253016509525
   PubMed Web of Science ®Google Scholar
• IervasiAIervasiGFerdeghiniM2007Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancerClin Endocrinol (Oxf)674344117555505
   PubMed Web of Science ®Google Scholar
• IorcanskySHerzovichVQualeyRR2005Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancerJ Clin Endocrinol Metab906553516174712
   PubMed Web of Science ®Google Scholar
• JarzabBHandkiewicz-JunakDRoskoszJ2003Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patientsEur J Nucl Med Mol Imaging3010778612783219
   PubMed Web of Science ®Google Scholar
• KimTYKimWBKimES2005Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinomaJ Clin Endocrinol Metab901440515613412
   PubMed Web of Science ®Google Scholar
• KloosRTMazzaferriEL2005A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years laterJ Clin Endocrinol Metab9050475715972576
   PubMed Web of Science ®Google Scholar
• LadensonPWBravermanLEMazzaferriEL1997Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinomaN Engl J Med337888969302303
   PubMed Web of Science ®Google Scholar
• LeboulleuxSSchroederPRSchlumbergerM2007The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancersNat Clin Pract Endocrinol Metab31122117237838
   PubMedGoogle Scholar
• LippiFCapezzoneMAngeliniF2001Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSHEur J Endocrinol14451111174831
   PubMed Web of Science ®Google Scholar
• LusterMFelbingerRDietleinM2005Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administrationThyroid1511475516279848
   PubMed Web of Science ®Google Scholar
• LusterMLassmannMHaenscheidH2000Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinomaJ Clin Endocrinol Metab853640511061516
   PubMed Web of Science ®Google Scholar
• LusterMShermanSISkarulisMC2003Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinomaEur J Nucl Med Mol Imaging301371712856155
   PubMed Web of Science ®Google Scholar
• MandacJCLeboeufRBrokhinM2008In properly selected patients, the results of a diagnostic whole-body RAI scan prior to RAI remnant ablation (RRA) seldom alters either the decision to proceed with RRA or the choice of administered activityThyroid18S36
   Google Scholar
• MandelSJMandelL2003Radioactive iodine and the salivary glandsThyroid132657112729475
   PubMed Web of Science ®Google Scholar
• MarianiGFerdeghiniMAugeriC2000Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancerCancer Biother Radiopharm15211710803328
   PubMed Web of Science ®Google Scholar
• MaxonHREnglaroEEThomasSR1992Radioiodine-131 therapy for well-differentiated thyroid cancer – a quantitative radiation dosimetric approach: outcome and validation in 85 patientsJ Nucl Med33113261597728
   PubMed Web of Science ®Google Scholar
• MazzaferriELRobbinsRJSpencerCA2003A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinomaJ Clin Endocrinol Metab8814334112679418
   PubMed Web of Science ®Google Scholar
• MeierCABravermanLEEbnerSA1994Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study)J Clin Endocrinol Metab78188968288703
   PubMed Web of Science ®Google Scholar
• MenzelCKranertWTDöbertN2003rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)IJ Nucl Med441065812843221
   PubMed Web of Science ®Google Scholar
• MernaghPCampbellSDietleinM2006Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspectiveEur J Endocrinol1554051416914594
   PubMed Web of Science ®Google Scholar
• MontesanoTDuranteCAttardM2007Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancerBiomed Pharmacother614687117553654
   PubMed Web of Science ®Google Scholar
• NiederkohrRDMcDougallIR2007Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropinEur J Nucl Med Mol Imaging34363717021814
   PubMed Web of Science ®Google Scholar
• PaciniFCapezzoneMEliseiR2002Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatmentJ Clin Endocrinol Metab87149950111932271
   PubMed Web of Science ®Google Scholar
• PaciniFCetaniFMiccoliP1994Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodineWorld J Surg1860047725751
   PubMed Web of Science ®Google Scholar
• PaciniFLadensonPWSchlumbergerM2006aRadioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled studyJ Clin Endocrinol Metab919263216384850
   PubMed Web of Science ®Google Scholar
• PaciniFMolinaroECastagnaMG2002Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawalJ Clin Endocrinol Metab874063812213846
   PubMed Web of Science ®Google Scholar
• PaciniFMolinaroECastagnaMG2003Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinomaJ Clin Endocrinol Metab8836687312915653
   PubMed Web of Science ®Google Scholar
• PaciniFSchlumbergerMDralleH2006bEuropean consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEur J Endocrinol15478780316728537
   PubMed Web of Science ®Google Scholar
• ParkSGReynoldsJCBrucker-DavisF1996Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs hypothyroidismJ Nucl Med3715
   Web of Science ®Google Scholar
• PellegritiGScolloCGiuffridaD2001Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancerThyroid1110253011762711
   PubMed Web of Science ®Google Scholar
• PilliTBrianzoniECapoccettiF2007A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancerJ Clin Endocrinol Metab923542617609306
   PubMed Web of Science ®Google Scholar
• PotziCMoameniAKaranikasG2006Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patientsClin Endocrinol (Oxf)655192316984246
   PubMed Web of Science ®Google Scholar
• RobbinsRJDriedgerAMagnerJ2006aRecombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxineThyroid1611213017123339
   PubMed Web of Science ®Google Scholar
• RobbinsRJLarsonSMPentlowKS2002aEffectiveness of I-131 in destroying metastatic thyroid cancer lesionsThyroid12199
   Google Scholar
• RobbinsRJLarsonSMSinhaN2002bA retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablationJ Nucl Med431482812411552
   PubMed Web of Science ®Google Scholar
• RobbinsRJTuttleRMSonenbergM2001Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropinThyroid11865911575856
   PubMed Web of Science ®Google Scholar
• RobbinsRJVoelkerEWangW2000Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literatureEndocr Pract6460411155220
   PubMedGoogle Scholar
• RobbinsRJWanQGrewalRK2006bReal-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-Dglucose- positron emission tomography scanningJ Clin Endocrinol Metab9149850516303836
   PubMed Web of Science ®Google Scholar
• RosarioPWBorgesMAPurischS2008Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicityJ Nucl Med4917768218927337
   PubMed Web of Science ®Google Scholar
• RosarioPWMaiaFFCardosoLD2004Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinomaClin Nucl Med293586115166882
   PubMed Web of Science ®Google Scholar
• RubinoCde VathaireFDottoriniME2003Second primary malignancies in thyroid cancer patientsBr J Cancer8916384414583762
   PubMed Web of Science ®Google Scholar
• RudavskyAZFreemanLM1997Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormoneJ Clin Endocrinol Metab821148989223
   PubMed Web of Science ®Google Scholar
• SandeepTCStrachanMWReynoldsRM2006Second primary cancers in thyroid cancer patients: a multinational record linkage studyJ Clin Endocrinol Metab9118192516478820
   PubMed Web of Science ®Google Scholar
• SchlesingerTFlowerMAMcCreadyVR1989Radiation dose assessments in radioiodine (131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroidRadiother Oncol1435412928556
   PubMed Web of Science ®Google Scholar
• SchlumbergerMBergGCohenO2004Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspectiveEur J Endocrinol1501051214763906
   PubMed Web of Science ®Google Scholar
• SchroederPRHaugenBRPaciniF2006A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawalJ Clin Endocrinol Metab918788416394083
   PubMed Web of Science ®Google Scholar
• SEER2008SEER Stat Fact Sheets – ThyroidSEER Cancer Statistics Review, 1975–2005Accessed 26 November 2008 URL: http://seer.cancer.gov/csr/1975_2005/
   Google Scholar
• SmallridgeRCMeekSEMorganMA2007Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patientsJ Clin Endocrinol Metab9282717077133
   PubMed Web of Science ®Google Scholar
• SzkudlinskiMWThotakuraNRBucciI1993Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivityEndocrinology13314905038404588
   PubMed Web of Science ®Google Scholar
• TaiebDLussatoDGuedjE2006Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapyThyroid16177916676403
   PubMed Web of Science ®Google Scholar
• TaiebDLussatoDMundlerO2004Subcutaneous administration of recombinant human thyrotropin as an alternative to thyroid hormone withdrawal in patients with anticoagulated thyroid cancer: preliminary resultsThyroid14463415242575
   PubMed Web of Science ®Google Scholar
• TaiebDSebagFCherenkoM2008Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled studyClin Endocrinol (Oxf)in press
   Web of Science ®Google Scholar
• TorlontanoMCrocettiUD’AloisoL2003Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancerEur J Endocrinol148192412534353
   PubMed Web of Science ®Google Scholar
• ToubeauMTouzeryCArveuxP2004Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancerJ Nucl Med459889415181134
   PubMed Web of Science ®Google Scholar
• TuttleRMBrokhinMOmryG2008Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawalJ Nucl Med497647018413378
   PubMed Web of Science ®Google Scholar
• VaianoAClaudio TrainoABoniG2007Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawalNucl Med Commun282152317264781
   PubMed Web of Science ®Google Scholar
• VargasGEUyHBazanC1999Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brainJ Clin Endocrinol Metab8438677110566621
   PubMed Web of Science ®Google Scholar
• VitaleGLupoliGACiccarelliA2003Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administrationJ Clin Endocrinol Metab8813192212629125
   PubMed Web of Science ®Google Scholar
• WangWLarsonSMFazzariM2000Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancerJ Clin Endocrinol Metab8511071310720047
   PubMed Web of Science ®Google Scholar
• Zanotti-FregonaraPDuronFKellerI2007Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH valuesNucl Med Commun28257917325587
   PubMed Web of Science ®Google Scholar